AR005280A1 - Forma de dosis efervescente unitaria multiple en tabletas, proceso para su fabricacion y uso de dicha forma para la fabricacion de medicamentos. - Google Patents
Forma de dosis efervescente unitaria multiple en tabletas, proceso para su fabricacion y uso de dicha forma para la fabricacion de medicamentos.Info
- Publication number
- AR005280A1 AR005280A1 ARP960105897A ARP960105897A AR005280A1 AR 005280 A1 AR005280 A1 AR 005280A1 AR P960105897 A ARP960105897 A AR P960105897A AR P960105897 A ARP960105897 A AR P960105897A AR 005280 A1 AR005280 A1 AR 005280A1
- Authority
- AR
- Argentina
- Prior art keywords
- manufacture
- enteric
- multiple unit
- dosage form
- units
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000011248 coating agent Substances 0.000 abstract 3
- 238000000576 coating method Methods 0.000 abstract 3
- 239000007938 effervescent tablet Substances 0.000 abstract 3
- 239000002702 enteric coating Substances 0.000 abstract 3
- 238000009505 enteric coating Methods 0.000 abstract 3
- 159000000011 group IA salts Chemical class 0.000 abstract 3
- 239000010410 layer Substances 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 2
- 239000000470 constituent Substances 0.000 abstract 2
- 239000011162 core material Substances 0.000 abstract 2
- 239000012055 enteric layer Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229960000381 omeprazole Drugs 0.000 abstract 2
- 229940126409 proton pump inhibitor Drugs 0.000 abstract 2
- 239000000612 proton pump inhibitor Substances 0.000 abstract 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 abstract 1
- 150000001447 alkali salts Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000007906 compression Methods 0.000 abstract 1
- 230000006835 compression Effects 0.000 abstract 1
- 230000027119 gastric acid secretion Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Una forma de dosis efervescente unitaria múltiple en tabletas que comprende constituyentes para tabletas efervescentes y unidades con revestimientos encapas entéricos de un material para núcleo que comprende un inhibidor bombeo protónicosusceptib le al ácido en la forma de un racemato, su sal alcalinao uno de sus enantiómeros simples o su sal alcalina, opcionalmente mezclado con compuestos alcalinos, el material del núcleo está revestido en capas con unao más capas derevestimiento, por lo me nos una de ellas es una capa de recubrimiento entérico donde las capa/s de revestimiento entérica/s tienenpropiedades mecánicas tales que la compresión de las unidades de revestimiento en capas entéricos con losconstituyentes para tabletas efervescentes dentrode la forma de dosis para tabletas unitaria múltiple no afecta significativamente la resistencia al ácido de las unidades con revestimiento encapas entéricos. El inhibidor bombeoprotónico preferentemente es omep razol o su sal alcalina, o S-omeprazol o su sal alcalina. Se provee un procedimientopara la fabricación de este tipo de formulación, y el uso de este tipo de formulación para preparar un medicamento parainhibir la secreción del ácidogástrico y para tratar las enfermedades inflamatorias gastrointestinales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9600073A SE512835C2 (sv) | 1996-01-08 | 1996-01-08 | Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR005280A1 true AR005280A1 (es) | 1999-04-28 |
Family
ID=20400971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960105897A AR005280A1 (es) | 1996-01-08 | 1996-12-26 | Forma de dosis efervescente unitaria multiple en tabletas, proceso para su fabricacion y uso de dicha forma para la fabricacion de medicamentos. |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US6132770A (es) |
| EP (1) | EP0814783B1 (es) |
| JP (1) | JP4638561B2 (es) |
| KR (1) | KR100459363B1 (es) |
| CN (1) | CN100335043C (es) |
| AR (1) | AR005280A1 (es) |
| AT (1) | ATE251451T1 (es) |
| AU (1) | AU712325B2 (es) |
| BR (1) | BR9607367A (es) |
| CA (1) | CA2214027C (es) |
| CZ (1) | CZ280797A3 (es) |
| DE (1) | DE69630286T2 (es) |
| DK (1) | DK0814783T3 (es) |
| EE (1) | EE9700189A (es) |
| ES (1) | ES2208775T3 (es) |
| HR (1) | HRP970005A2 (es) |
| HU (1) | HUP0000976A3 (es) |
| ID (1) | ID15819A (es) |
| IL (1) | IL121653A (es) |
| IS (1) | IS4551A (es) |
| MX (1) | MX9706768A (es) |
| NO (1) | NO319999B1 (es) |
| NZ (1) | NZ325978A (es) |
| PL (1) | PL322161A1 (es) |
| PT (1) | PT814783E (es) |
| SE (1) | SE512835C2 (es) |
| SI (1) | SI0814783T1 (es) |
| SK (1) | SK117197A3 (es) |
| TN (1) | TNSN97002A1 (es) |
| TR (1) | TR199700918T1 (es) |
| WO (1) | WO1997025030A1 (es) |
| YU (1) | YU70196A (es) |
| ZA (1) | ZA9610939B (es) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6558952B1 (en) * | 1992-12-14 | 2003-05-06 | Waratah Pharmaceuticals, Inc. | Treatment for diabetes |
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6699885B2 (en) | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
| US20050054682A1 (en) * | 1996-01-04 | 2005-03-10 | Phillips Jeffrey O. | Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same |
| SE512835C2 (sv) * | 1996-01-08 | 2000-05-22 | Astrazeneca Ab | Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare |
| SE9702533D0 (sv) | 1997-07-01 | 1997-07-01 | Astra Ab | New oral formulation |
| PT1037607E (pt) * | 1997-12-08 | 2004-07-30 | Altana Pharma Ag | Nova forma de supositorio compreendendo um composto activo instavel em acido |
| CA2320963A1 (en) * | 1998-01-30 | 1999-08-05 | Sepracor, Inc. | R-lansoprazole compositions and methods |
| WO1999059544A2 (en) * | 1998-05-18 | 1999-11-25 | Takeda Chemical Industries, Ltd. | Orally disintegrable tablets |
| TW585786B (en) * | 1998-07-28 | 2004-05-01 | Takeda Chemical Industries Ltd | Lansoprazole-containing rapidly disintegrable solid pharmaceutical composition |
| AU4040800A (en) * | 1999-03-29 | 2000-10-16 | American Home Products Corporation | Coating system |
| US6174902B1 (en) | 1999-04-28 | 2001-01-16 | Sepracor Inc. | R-rabeprazole compositions and methods |
| UA74339C2 (uk) | 1999-06-07 | 2005-12-15 | Алтана Фарма Аг | Форма для введення, що включає інгібітор протонної помпи у вигляді окремих одиниць, та спосіб їх одержання |
| US6316020B1 (en) | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
| WO2002026210A2 (en) * | 2000-09-29 | 2002-04-04 | Geneva Pharmaceuticals Inc. | Proton pump inhibitor formulation |
| UA80393C2 (uk) | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці |
| DK1341528T3 (da) | 2000-12-07 | 2012-03-26 | Nycomed Gmbh | Hurtigtopløsende tablet omfattende en syrelabil aktiv bestanddel |
| US20020192299A1 (en) * | 2000-12-28 | 2002-12-19 | Rajneesh Taneja | Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination |
| WO2003063840A2 (en) * | 2002-01-25 | 2003-08-07 | Santarus, Inc. | Transmucosal delivery of proton pump inhibitors |
| MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| CA2480385A1 (en) | 2002-03-27 | 2003-10-02 | Altana Pharma Ag | Alkoxypyridine derivatives as nitric oxide synthase inhibitors |
| FR2838647B1 (fr) * | 2002-04-23 | 2006-02-17 | Particules enrobees a liberation prolongee, leur procede de preparation et comprimes les contenant | |
| US20030228363A1 (en) * | 2002-06-07 | 2003-12-11 | Patel Mahendra R. | Stabilized pharmaceutical compositons containing benzimidazole compounds |
| US20040082618A1 (en) * | 2002-07-03 | 2004-04-29 | Rajneesh Taneja | Liquid dosage forms of acid labile drugs |
| US20040005362A1 (en) * | 2002-07-03 | 2004-01-08 | Rajneesh Taneja | Liquid dosage forms of acid labile drugs |
| US20070243251A1 (en) * | 2002-12-20 | 2007-10-18 | Rajneesh Taneja | Dosage Forms Containing A PPI, NSAID, and Buffer |
| US20040121004A1 (en) * | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
| US20040166162A1 (en) * | 2003-01-24 | 2004-08-26 | Robert Niecestro | Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid |
| BRPI0406427B8 (pt) | 2003-03-10 | 2021-05-25 | Astrazeneca Ab | processo para a preparação de roflumilast |
| WO2004082679A1 (ja) * | 2003-03-17 | 2004-09-30 | Takeda Pharmaceutical Company Limited | 放出制御組成物 |
| ES2234393B2 (es) * | 2003-04-29 | 2006-09-01 | Laboratorios Belmac, S.A. | "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido". |
| CL2004000983A1 (es) * | 2003-05-08 | 2005-03-04 | Altana Pharma Ag | Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y |
| PE20050150A1 (es) * | 2003-05-08 | 2005-03-22 | Altana Pharma Ag | Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo |
| TWI398273B (zh) * | 2003-07-18 | 2013-06-11 | Santarus Inc | 用於抑制酸分泌之醫藥調配物及其製備及使用之方法 |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| KR20060092221A (ko) | 2003-10-01 | 2006-08-22 | 알타나 파마 아게 | 유도성 ｎｏ-신타제 억제제로서의이미다조（4,5-ｂ）피리딘 유도체 |
| US7468377B2 (en) | 2003-10-01 | 2008-12-23 | Altana Pharma Ag | Imidazopyridine-derivatives as inductible no-synthase inhibitors |
| DE602004014628D1 (de) | 2003-10-01 | 2008-08-07 | Nycomed Gmbh | Imidazopyridin-derivate und ihre verwendung als induzierbare no-synthase inhibitoren |
| CA2540230A1 (en) * | 2003-10-01 | 2005-07-07 | Altana Pharma Ag | Aminopyridine-derivatives as inductible no-synthase inhibitors |
| US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| WO2006097456A1 (en) | 2005-03-16 | 2006-09-21 | Nycomed Gmbh | Taste masked dosage form containing roflumilast |
| US7803817B2 (en) | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
| US7981908B2 (en) | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
| SI1931316T1 (sl) * | 2005-08-15 | 2010-06-30 | Solvay Pharm Gmbh | Farmacevtski sestavki z nadzorovanim sproščanjem za kislinsko labilna zdravila |
| EP1785135A1 (en) * | 2005-11-10 | 2007-05-16 | Laboratorios Del Dr. Esteve, S.A. | New stabilized galenic formulations comprising lansoprazole and their preparation |
| US20070141151A1 (en) * | 2005-12-20 | 2007-06-21 | Silver David I | Lansoprazole orally disintegrating tablets |
| WO2007090113A2 (en) | 2006-02-01 | 2007-08-09 | Weg Stuart L | Use of antifungal compositions to treat upper gastrointestinal conditions |
| EP1837016A3 (en) * | 2006-03-08 | 2008-01-02 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical multiple-unit composition |
| EP1834634A3 (en) * | 2006-03-08 | 2007-10-03 | Rentschler Pharma GmbH | Pharmaceutical multiple-unit composition |
| WO2007122478A2 (en) * | 2006-04-20 | 2007-11-01 | Themis Laboratories Private Limited | Multiple unit compositions |
| CA2654402A1 (en) * | 2006-06-01 | 2007-12-06 | Adel Penhasi | Multiple unit pharmaceutical formulation |
| ES2511792T3 (es) * | 2006-07-25 | 2014-10-23 | Vecta Ltd. | Composiciones y métodos para la inhibición de la secreción de ácido gástrico usando derivados de pequeños ácidos dicarboxílicos en combinación con IBP |
| EP2044929A1 (en) * | 2007-10-04 | 2009-04-08 | Laboratorios del Dr. Esteve S.A. | Oral fast distintegrating tablets |
| EP2044932A1 (en) * | 2007-10-04 | 2009-04-08 | Laboratorios del Dr. Esteve S.A. | Mechanical protective layer for solid dosage forms |
| AU2015316552C1 (en) | 2014-09-17 | 2018-08-23 | Steerlife India Private Limited | Effervescent composition and method of making it |
| EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| WO2017098481A1 (en) | 2015-12-12 | 2017-06-15 | Steerlife India Private Limited | Effervescent compositions of metformin and processes for preparation thereof |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| US10583089B2 (en) * | 2016-07-19 | 2020-03-10 | Johnson & Johnson Consumer Inc. | Tablets having discontinuous coated regions |
| CN112574835A (zh) * | 2019-09-30 | 2021-03-30 | 埃科莱布美国股份有限公司 | 泡腾片清洁剂及其用途 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5535031A (en) * | 1978-09-04 | 1980-03-11 | Shin Etsu Chem Co Ltd | Enteric coating composition |
| JPS5598120A (en) * | 1979-01-16 | 1980-07-25 | Shin Etsu Chem Co Ltd | Preparation of drug having enteric coating |
| US4289751A (en) * | 1979-06-29 | 1981-09-15 | Merck & Co., Inc. | Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof |
| FR2471186A1 (fr) * | 1979-12-10 | 1981-06-19 | Roussel Uclaf | Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation |
| US4340582A (en) * | 1981-01-15 | 1982-07-20 | Abbott Laboratories | Erythromycin base tablets |
| US4377568A (en) * | 1981-08-12 | 1983-03-22 | Merck Sharp & Dohme (I.A.) Corp. | Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same |
| DK150008C (da) * | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
| JPS5973529A (ja) * | 1982-10-12 | 1984-04-25 | Sankyo Co Ltd | 被覆固形製剤の製造法 |
| US4525339A (en) * | 1982-10-15 | 1985-06-25 | Hoffmann-La Roche Inc. | Enteric coated oral dosage form |
| US4518433A (en) * | 1982-11-08 | 1985-05-21 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
| GB2132887A (en) * | 1982-11-15 | 1984-07-18 | Procter & Gamble | Enteric-coated anti-inflammatory compositions |
| US4503031A (en) * | 1982-12-17 | 1985-03-05 | Glassman Jacob A | Super-fast-starting-sustained release tablet |
| US4556552A (en) * | 1983-09-19 | 1985-12-03 | Colorcon, Inc. | Enteric film-coating compositions |
| JPH0759499B2 (ja) * | 1984-02-10 | 1995-06-28 | ベンツォン ファーマ エイ／エス | 拡散被覆された複合単位服用剤 |
| US4568560A (en) * | 1984-03-16 | 1986-02-04 | Warner-Lambert Company | Encapsulated fragrances and flavors and process therefor |
| WO1986007348A1 (en) * | 1985-06-03 | 1986-12-18 | Hughes Aircraft Company | Method for introducing dopants in optical fiber preforms |
| SE450087B (sv) * | 1985-10-11 | 1987-06-09 | Haessle Ab | Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial |
| FR2593065B1 (fr) * | 1986-01-22 | 1988-09-09 | Smith Kline French Lab | Couples effervescents, compositions effervescentes d'antagonistes h2 de l'histamine les contenant et leur preparation. |
| GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| GB2189699A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| GB8724763D0 (en) * | 1987-10-22 | 1987-11-25 | Aps Research Ltd | Sustained-release formulations |
| JPH0768125B2 (ja) * | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | 酸不安定化合物の内服用製剤 |
| FR2633181B1 (fr) * | 1988-06-24 | 1992-01-10 | Glaxo Lab Sa | Composition pharmaceutique a base de ranitidine et son procede de preparation |
| US5026559A (en) * | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
| JP3142919B2 (ja) * | 1991-11-06 | 2001-03-07 | 旭化成株式会社 | セルロース誘導体ラテックス及びその製法 |
| US5160742A (en) * | 1991-12-31 | 1992-11-03 | Abbott Laboratories | System for delivering an active substance for sustained release |
| EP0555931A1 (en) * | 1992-02-14 | 1993-08-18 | Shell Internationale Researchmaatschappij B.V. | Isoxazole derivatives and their use as pesticides |
| JPH0733659A (ja) * | 1992-07-17 | 1995-02-03 | Yoshitomi Pharmaceut Ind Ltd | 抗潰瘍剤含有製剤 |
| KR970011587B1 (ko) * | 1992-07-31 | 1997-07-12 | 삼성전자 주식회사 | Mac 시스템의 프레임 싱크 검출회로 |
| ATE217188T1 (de) * | 1992-08-05 | 2002-05-15 | Faulding F H & Co Ltd | Granulierte pharmazeutische zusammensetzung |
| US5330759A (en) * | 1992-08-26 | 1994-07-19 | Sterling Winthrop Inc. | Enteric coated soft capsules and method of preparation thereof |
| US5503846A (en) * | 1993-03-17 | 1996-04-02 | Cima Labs, Inc. | Base coated acid particles and effervescent formulation incorporating same |
| SE9302395D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | New pharmaceutical formulation |
| JP3017906B2 (ja) * | 1993-10-08 | 2000-03-13 | 信越化学工業株式会社 | 腸溶性コーティング剤分散液 |
| AU683092B2 (en) * | 1993-10-12 | 1997-10-30 | Mitsubishi-Tokyo Pharmaceuticals, Inc. | Tablet containing enteric granules |
| GB2285989A (en) * | 1994-01-28 | 1995-08-02 | Merck Frosst Canada Inc | Aqueous formulations for enteric coatings |
| SI1078628T1 (sl) * | 1994-07-08 | 2009-04-30 | Astrazeneca Ab | Večenotska tabletirana dozirna oblika |
| SE9402431D0 (sv) * | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
| US5824339A (en) * | 1995-09-08 | 1998-10-20 | Takeda Chemical Industries, Ltd | Effervescent composition and its production |
| US5840737A (en) * | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| SE9600070D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| SE512835C2 (sv) * | 1996-01-08 | 2000-05-22 | Astrazeneca Ab | Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare |
-
1996
- 1996-01-08 SE SE9600073A patent/SE512835C2/sv not_active IP Right Cessation
- 1996-12-20 EP EP96944727A patent/EP0814783B1/en not_active Expired - Lifetime
- 1996-12-20 KR KR1019970706237A patent/KR100459363B1/ko not_active Expired - Fee Related
- 1996-12-20 CN CNB961937637A patent/CN100335043C/zh not_active Expired - Lifetime
- 1996-12-20 SK SK1171-97A patent/SK117197A3/sk unknown
- 1996-12-20 CZ CZ972807A patent/CZ280797A3/cs unknown
- 1996-12-20 DE DE69630286T patent/DE69630286T2/de not_active Expired - Lifetime
- 1996-12-20 WO PCT/SE1996/001738 patent/WO1997025030A1/en not_active Ceased
- 1996-12-20 HU HU0000976A patent/HUP0000976A3/hu unknown
- 1996-12-20 IL IL12165396A patent/IL121653A/en not_active IP Right Cessation
- 1996-12-20 PT PT96944727T patent/PT814783E/pt unknown
- 1996-12-20 AT AT96944727T patent/ATE251451T1/de not_active IP Right Cessation
- 1996-12-20 JP JP52513297A patent/JP4638561B2/ja not_active Expired - Lifetime
- 1996-12-20 PL PL96322161A patent/PL322161A1/xx unknown
- 1996-12-20 MX MX9706768A patent/MX9706768A/es not_active IP Right Cessation
- 1996-12-20 EE EE9700189A patent/EE9700189A/xx unknown
- 1996-12-20 SI SI9630657T patent/SI0814783T1/xx unknown
- 1996-12-20 BR BR9607367A patent/BR9607367A/pt not_active IP Right Cessation
- 1996-12-20 NZ NZ325978A patent/NZ325978A/xx unknown
- 1996-12-20 DK DK96944727T patent/DK0814783T3/da active
- 1996-12-20 TR TR97/00918T patent/TR199700918T1/xx unknown
- 1996-12-20 AU AU13242/97A patent/AU712325B2/en not_active Ceased
- 1996-12-20 US US08/793,077 patent/US6132770A/en not_active Expired - Lifetime
- 1996-12-20 CA CA002214027A patent/CA2214027C/en not_active Expired - Lifetime
- 1996-12-20 ES ES96944727T patent/ES2208775T3/es not_active Expired - Lifetime
- 1996-12-26 YU YU70196A patent/YU70196A/sh unknown
- 1996-12-26 AR ARP960105897A patent/AR005280A1/es unknown
- 1996-12-30 ZA ZA9610939A patent/ZA9610939B/xx unknown
-
1997
- 1997-01-03 HR HR9600073-2A patent/HRP970005A2/hr not_active Application Discontinuation
- 1997-01-06 TN TNTNSN97002A patent/TNSN97002A1/fr unknown
- 1997-01-08 ID IDP970023A patent/ID15819A/id unknown
- 1997-08-25 IS IS4551A patent/IS4551A/is unknown
- 1997-09-03 NO NO19974051A patent/NO319999B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR005280A1 (es) | Forma de dosis efervescente unitaria multiple en tabletas, proceso para su fabricacion y uso de dicha forma para la fabricacion de medicamentos. | |
| ATE414509T1 (de) | Aus vielen einzeleinheiten zusammengesetzte tablettierte dosisform | |
| AR005282A1 (es) | Composición farmacéutica oral en la forma de un comprimido de unidades múltiples, uso de la misma para la preparación de medicamnetos, y procedimiento para su manufactura. | |
| DK0854718T3 (da) | Hidtil ukendt sammensætning indeholdende en syrelabil benzimidazol og fremgangsmåde til fremstilling deraf | |
| MX9604354A (es) | Nueva forma de dosis farmaceutica oral. | |
| ES2168043A1 (es) | Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido. | |
| MX9706769A (es) | Formas de dosificacion farmaceutica que comprenden un inhibidor de la bomba de protones y un agente procinetico. | |
| ES507236A0 (es) | Un procedimiento para preparar una composicion farmaceutica para aplicacion topica, empleada en el tratamiento del acne. | |
| DE60229295D1 (de) | Komprimierte, orale pharmazeutische dosierungsform mit enterischer beschichtung, die eine säurelabile benzimidazolverbindung enthält | |
| CN204428461U (zh) | 埃索美拉唑碳酸氢钠片中片 | |
| RU96107097A (ru) | Составная единичная дозированная форма в виде таблетки, содержащая ингибитор протонного насоса | |
| CO5690559A2 (es) | Bayer healthcare ag. medicamentos que contienen clorhidrato de vardenafilo trihidrato | |
| MX9600856A (es) | Preparacion farmaceutica de unidades multiples, que contienen un inhibidor de la bomba de protones. | |
| TH79788A (th) | สูตรผสมยาเม็ดที่มีการปลดปล่อยดัดแปรชนิดใหม่สำหรับตัวยับยั้งการปั๊มโปรตอน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |